Pharma Invest Devos
ActivePharma Invest Devos has been active since 2008 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €618k and a net result of €62k. Equity is growing by ~7.9% per year across the filed fiscal years. Its solvency ranks better than 84% of 18016 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Checked score
Score 2025
68
/ 100
Healthy▲ +20 vs 2024
The score combines four axes. Every signal that weighs is under Signals.
Axes · tick = 2024
Profitability50▲+19
Solvency70▲+3
Growth78▲+26
Stability100
Bankruptcy probability, 12 months
0.6%
Low
0%0.5%1.5%4%10%≥ 25%
Credit up to €40k at 30 days acceptable
Liquidity short (current ratio 0.65 against 0.25 in 2024), and 24.8% of the assets are financed with debt.
Credit advice for your own amount and term
Signals
Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Higher-failure-rate sector
In this sector companies fail more often than the Belgian average.
Gazette · bankruptcies per sector, NACE 47
Relative position
BE, all sectors
reference
Sector 47
higher
← fewer bankruptcies
more bankruptcies →
lowers risk · Long track record
A company with a long track record statistically fails less often than a young one.
KBO · incorporation dateAge against the risk zone
lowers risk · Annual accounts: healthy financial profile
The latest annual accounts show a healthy profile in solvency, result and liquidity.
NBB · annual accounts 2025Solvency, return and age of the figures
Solvency
75.2%
Return on assets
7.5%
Age of the figures
14 mo
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 05-01-2026, 26 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
26 d early
2024
25 d early
2023
26 d early
2022
27 d early
2021
26 d early
2020
25 d early
2019
25 d early
← before the deadline
after the deadline →
neutral · The next deadline is still running
The next financial year closes on 30-06-2026 and is due by 31-01-2027. Nothing is late today.
Companies Code · seven monthsPosition in the running window
30-06-2026 close14-09-2026 today31-01-2027 deadline
Financials · fiscal year 2025, micro schema
Equity
€618k▲ 11.1%
2024 · €556k
2019: €385k
2020: €416k
2021: €450k
2022: €484k
2023: €521k
2024: €556k
2019 → 2025
Total assets
€822k▲ 10.6%
2024 · €743k
2019: €754k
2020: €739k
2021: €734k
2022: €728k
2023: €716k
2024: €743k
2019 → 2025
Net result
€62k▲ 76.9%
2024 · €35k
2019: €39k
2020: €33k
2021: €34k
2022: €35k
2023: €37k
2024: €35k
2019 → 2025
Working capital
€-66k▲ 50.2%
2024 · €-132k
2019: €-137k
2020: €-155k
2021: €-172k
2022: €-188k
2023: €-164k
2024: €-132k
2019 → 2025
Multi-year overview
Every figure with its change against the year before
▲ rise
▼ fall
Line20212022202320242025Trend
Equity€450k-€484k▲ 7.7%€521k▲ 7.6%€556k▲ 6.7%€618k▲ 11.1%
Operating result€59k-€59k▼ 0.8%€60k▲ 1.1%€58k▼ 3.1%€98k▲ 70.2%
Net result€34k-€35k▲ 3.5%€37k▲ 6.5%€35k▼ 5.5%€62k▲ 76.9%
Turnover and EBIT margin not published: the abbreviated or micro schema does not require them.
Result per fiscal year
Operating resultNet result
The operating result recovers in 2025; 2025 is 70% above 2024 and is the highest year so far.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €822k
Fixed assets
€700k=
Current assets
€122k▲ 183%
Equity and liabilities €822k
Equity
€618k▲ 11.1%
Debt
€203k▲ 9.0%
The debt ratio falls from 25.1% to 24.8%: equity grows faster than debt.
Key figures and ratios
Solvency
75.2%▲
2024 · 74.9%
Current ratio
0.65▲
2024 · 0.25
Quick ratio
0.65▲
2024 · 0.25
Debt / equity
0.33▼
2024 · 0.34
ROE
10.0%▲
2024 · 6.3%
ROA
7.5%▲
2024 · 4.7%
Debt
€203k▲
2024 · €187k
Debt ≤ 1 year
€187k▲
2024 · €175k
Income taxes
€23k▲
2024 · €13k
Staff costs
€2k▼
2024 · €3k
Green means a favourable move, even when the figure itself falls: as with debt or debt / equity.
Filed annual accounts
As filed with the NBB · 2025 against 2024
Balance sheet
Code20242025
Assets
Total assets20/58€743k€822k▲
Fixed assets21/28€700k€700k=
Financial fixed assets28€700k€700k=
Current assets29/58€43k€122k▲
Amounts receivable within one year40/41€16k€110k▲
Trade receivables40-€47k
Other amounts receivable41€16k€62k▲
Cash at bank and in hand54/58€26k€11k▼
Deferred charges and accrued income490/1€1k€1k▼
Equity and liabilities
Total equity and liabilities10/49€743k€822k▲
Equity10/15€556k€618k▲
Contributions10/11€12k€12k=
Outside capital11€12k€12k=
Other1109/19€12k€12k=
Reserves13€544k€606k▲
Non-distributable reserves130/1€2k€2k=
Reserves not available under the articles1311€2k€2k=
Distributable reserves133€542k€604k▲
Amounts payable17/49€187k€203k▲
Amounts payable within one year42/48€175k€187k▲
Trade debts44€587€2k▲
Suppliers440/4€587€2k▲
Taxes, remuneration and social security45€9k€12k▲
Taxes450/3€8k€12k▲
Remuneration and social security454/9€386€96▼
Other amounts payable47/48€166k€174k▲
Accrued charges and deferred income492/3€11k€16k▲
Income statement
Code20242025
Remuneration, social security and pensions62€3k€2k▼
Other operating charges640/8€738€689▼
Gross operating margin9900€62k€101k▲
Operating profit (loss)9901€58k€98k▲
Financial income75/76B-€591
Recurring financial income75-€591
Financial charges65/66B€10k€14k▲
Recurring financial charges65€10k€14k▲
Profit (loss) for the period before taxes9903€48k€85k▲
Income taxes67/77€13k€23k▲
Profit (loss) for the period9904€35k€62k▲
Profit (loss) for the period to be appropriated9905€35k€62k▲
Appropriation of the result
Profit (loss) to be appropriated9906€35k€62k▲
Transfer to equity691/2€35k€62k▲
To other reserves6921€35k€62k▲
The notes to these accounts (4 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.
Timeline · acts, filings and financial milestones
Next filing, fiscal year 2026, expected by
2026
05-01
NBB filing
Annual accounts filed
fiscal year 2025 · micro schema
2025
30-06
Financial
Highest result since 2019net €62k ▲76.9%
Operating result €98k, net result €62k, both a record.
06-01
NBB filing
Annual accounts filed
fiscal year 2024 · micro schema
2024
05-01
NBB filing
Annual accounts filed
fiscal year 2023 · micro schema
2023
30-06
Financial
Equity above €500kEq €521k ▲7.6%
5 profitable years in a row build equity to €521k.
04-01
NBB filing
Annual accounts filed
fiscal year 2022 · micro schema
2022
05-01
NBB filing
Annual accounts filed
fiscal year 2021 · abbreviated schema
2021
06-01
NBB filing
Annual accounts filed
fiscal year 2020 · micro schema
2020
30-06
Financial
Weakest financial yearnet €33k ▼14.9%
Net result drops to €33k, the lowest in the series; recovery starts the following year.
06-01
NBB filing
Annual accounts filed
fiscal year 2019 · micro schema
2018
27-12
NBB filing
Annual accounts filed
fiscal year 2018 · micro schema
02-01
NBB filing
Annual accounts filed
fiscal year 2017 · abbreviated schema
2017
03-01
NBB filing
Annual accounts filed
fiscal year 2016 · abbreviated schema
Financial milestoneNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.
Directors · office · real estate
Directors
1 act for this company is in the Belgian State Gazette, of which we have read 0. We have therefore not extracted its directors from those acts yet.
Location & real-estate footprint
Registered office, Halle · 1 establishment unit since 2008
Cannot be placed on the map
This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.
Alsembergsesteenweg 911501 HalleGround area
354 m²
Building footprint
211 m²
Volume, LiDAR
1,815 m³
Parcel 23013A0019/02X000, Flanders · tallest building 10.7 m, ±3 floors. Linked by address, not a title deed.
1 establishment unit
Pharma Invest Devos
since 20082.174.124.544
1 parcel
Flanders
1
(100%)
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 23013A0019/02X000 | Flanders | 354 m² | 1 · 211 m² | 10.7 m · 3 fl. |
Linked by address, not proof of ownership
Methodology
via registered seat: 1
1 of 1 parcel with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.
Similar companies · same sector, comparable size
APOTHEKER STEVEN VRIJDAG
BE 0817.319.624
Dendermonde · Eq €618k
MOERMAN ANN
BE 0808.468.175
Knokke-Heist · Eq €619k
APOTHEEK HECHTEL
BE 0791.683.712
Hechtel-Eksel · Eq €619k
APOTHEEK D. DUBOIS
BE 0442.276.646
Kortrijk · Eq €617k
SANIMED
BE 0448.804.548
Oudenburg · Eq €619k
Of 5,209 companies in sector 47730 we hold annual accounts for 3,851. 3,267 are within a factor 10 of this equity.See the whole sector
Company data · Crossroads Bank
Identification
Legal formPrivate limited company (pre-2019)
Founded20-08-2008
Fiscal year end30-06
Activities, NACEBEL
47730Retail sale of pharmaceutical products
Sources
Crossroads Bank for EnterprisesNational Bank · 17 filingsAddress and cadastre registers
Data from official sources, last processed on 14-09-2026. Scores and ratios are computed by Checked and are not a credit decision.